

# BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001.  
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

14<sup>th</sup> August, 2019

To,  
Department of Corporate Service  
Corporate Relation Department  
**Bombay Stock Exchange Ltd.,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

**BSE Script Code: 524516**

**Sub.: Unaudited Financial Results for the Quarter ended 30th June, 2019**

Dear Sir/Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following;

1. Unaudited Financial Results of the Company for the Quarter ended 30th June, 2019 duly approved and taken on record by the Board of Directors of the Company.
2. Auditors' Limited Review Report on the above Unaudited Financial Results issued by the Statutory Auditors of the Company and taken on record by the Board of Directors of the Company.

The Board Meeting was concluded at 08:00 p.m.

You are hereby requested to take the same on records.

Thanking You

Yours Faithfully  
For **Bacil Pharma Ltd.**



Director



Enclosure: As above

# BACIL PHARMA LIMITED

CIN:L24200MH1987PLC043427

## UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2019

(Amount in Lacs)

Sr. No.	Particulars	Quarter ended			Year ended
		30/06/2019	31/03/2019	30/06/2018	31/03/2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-
	Other income	1.62	4.71	2.27	9.41
	<b>Total revenue</b>	<b>1.62</b>	<b>4.71</b>	<b>2.27</b>	<b>9.41</b>
2	<b>Expenses</b>				
	Employee benefits expense	1.90	1.22	2.36	7.87
	Depreciation and amortization expense	0.21	0.26	0.22	0.91
	Other expenses	4.98	8.56	9.14	34.97
	<b>Total expenses</b>	<b>7.09</b>	<b>10.03</b>	<b>11.72</b>	<b>43.76</b>
3	<b>Profit before exceptional items and tax</b>	<b>(5.47)</b>	<b>(5.32)</b>	<b>(9.45)</b>	<b>(34.35)</b>
	Exceptional items	-	-	-	-
	<b>Profit / (Loss) from ordinary activities before tax</b>	<b>(5.47)</b>	<b>(5.32)</b>	<b>(9.45)</b>	<b>(34.35)</b>
4	<b>Tax expense:</b>				
	(1) Current tax	-	-	-	-
	(2) Earlier year's Tax	-	-	-	-
	(3) Deferred tax	-	(0.11)	(0.03)	(0.11)
5	<b>Profit/(Loss) from ordinary activities after tax</b>	<b>(5.47)</b>	<b>(5.21)</b>	<b>(9.42)</b>	<b>(34.24)</b>
6	<b>Other Comprehensive Income (OCI)</b>				
	Item that will not be reclassified to profit or loss				
	Gain/(Loss) on recognised on fair valuation of Financial Assets	(12.78)	8.21	(16.86)	(0.26)
	Income tax relating to these items	3.32	(2.00)	4.34	1.92
	<b>Total Other Comprehensive Income (OCI)</b>	<b>(9.46)</b>	<b>6.21</b>	<b>(12.52)</b>	<b>1.66</b>
	<b>Profit/(Loss) for the Period</b>	<b>(14.93)</b>	<b>1.00</b>	<b>(21.94)</b>	<b>(32.58)</b>
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589.00	589.00	589.00	589.00
7	<b>Earning Per Share (EPS) (Not annualised)</b>				
	(1) Basic	(0.09)	(0.09)	(0.16)	(0.58)
	(2) Diluted	(0.09)	(0.09)	(0.16)	(0.58)

**Notes:**

- 1 The Above Financial Results were reviewed by the audit committee of the board on 14th August, 2019 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- 2 Figures for the corresponding quarter ended i.e. 31st March 2019 in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year.
- 3 The company has adopted Indian Accounting Standard (Ind AS) effective from 1st April' 2017 (Transition date being 1st April' 2016) and accordingly the financial results for the quarter 30th June 2018 have been prepared in accordance with the recognition and measurement principles laid down in Ind As-34 Interim Financial Reporting prescribed under section 133 of the Companies Act' 2013.
- 4 The Company has single business segment therefore in the context of Ind As 108, disclosure of segment information is not applicable.
- 5 Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.

For BACIL PHARMA LIMITED

Director




Place: Mumbai

Dated: 14th August 2019



# Laxmikant Kabra & Co.

## Chartered Accountants

### INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

TO,

**THE BOARD OF DIRECTORS OF BACIL PHARMA LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Bacil Pharma Limited** ("the Company") for the quarter ended June 30, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Also the figures up to the quarter ended were only reviewed and not subjected to audit. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing Obligation And Disclosure Requirements) Regulation, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*For Laxmikant Kabra & Co.*  
*Chartered Accountants*  
*Firm Registration No.: 117183W*

*L.K. Kabra*  
**CA Laxmikant Kabra**  
*(Partner)*  
**Membership No.: 101839**



*Place: Thane,*  
*Date: 14<sup>th</sup> August, 2019*  
**UDIN: 19101839AAAACW8729**